Cartesian Therapeutics (RNAC) Liabilities and Shareholders Equity (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $288.4 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $288.4 million, down 29.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 18.26% YoY), and the FY2025 annual result was $296.4 million, down 31.86% from the prior year.
• Liabilities and Shareholders Equity slipped to $288.4 million in Q1 2026 per RNAC's latest filing, from $296.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $455.3 million in Q3 2024 and troughed at $106.0 million in Q3 2023.
• A 5-year average of $276.6 million and a median of $296.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity slumped 40.52% in 2023, then soared 329.41% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $165.9 million in 2022, then jumped by 83.89% to $305.0 million in 2023, then soared by 42.61% to $435.0 million in 2024, then plunged by 31.86% to $296.4 million in 2025, then fell by 2.71% to $288.4 million in 2026.
• Business Quant data shows RNAC's Liabilities and Shareholders Equity at $288.4 million in Q1 2026, $296.4 million in Q4 2025, and $372.7 million in Q3 2025.